This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum
Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma
False
Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
September 9, 2026
5 min read
Lonza’s Wayne Wen discusses the growing maturity of China’s drug development and manufacturing ecosystem – and what companies need to compete internationally
September 1, 2026
7 min read
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han
August 31, 2026
4 min read
New approaches to oligonucleotide production, mRNA design, and supply chain control could help turn promising nucleic acid therapies into scalable commercial products
August 31, 2026
4 min read
A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors
False
Affiliations:
Specialties:
Areas of Expertise: